Why the study?
Digital health technology-based chronic disease management platforms combined with smart hypertension models may improve patient self-management, but their effect on systolic blood pressure needed evaluation.
Does a digital health technology-based chronic disease management platform combined with an intelligent hypertension management model reduce systolic blood pressure in adults with uncontrolled hypertension?
Does a digital health technology-based chronic disease management platform combined with an intelligent hypertension management model reduce systolic blood pressure in adults with uncontrolled hypertension?
A digital health technology-based intelligent management platform significantly reduced systolic blood pressure at 12 months in adults with uncontrolled hypertension compared to traditional offline management.
Supports digital platforms for hypertension management; extends RCT evidence for technology-based models in uncontrolled hypertension.
Importance Digital health technology (DHT)-based chronic disease management platforms combined with smart hypertension models may improve patient self-management. Objective To compare the effect of Nantong University Affiliated Hospital's DHT platform combined with an intelligent hypertension management model (providing education, follow-up, evaluation) vs. traditional offline management on patients' systolic blood pressure (SBP). Design, setting, and participants This was a two-arm, parallel-group randomized controlled trial conducted from July 2023 to March 2025. Participants were adults (≥18 years) with hypertension and uncontrolled blood pressure. Interventions Participants were randomly assigned using computer-generated sequences to an integrated digital health platform with intelligent hypertension management (intervention, n = 285) or to traditional offline management (control, n = 285). Main outcomes Primary outcome: SBP at 12 months. Secondary outcomes: Diastolic blood pressure (DBP), BMI, biochemical/metabolic parameters (e.g., cholesterol, glucose, creatinine), and healthcare costs. Results 547 participants completed the study (Intervention: n = 273; Control: n = 274). The intervention group achieved a greater reduction in SBP at 12 months (adjusted between-group difference: −3.14 mmHg, 95% CI: −5.24 to −1.03, P = 0.004). Subgroup analysis revealed significant heterogeneity by baseline SBP (interaction P < 0.001). For participants with baseline SBP below the median (<146 mmHg), the intervention group achieved a significantly larger SBP reduction (between-group difference: −6.79 mmHg, 95% CI: −9.62 to −3.96). It is expected that a decrease of 5 mmHg can reduce the risk of cardiovascular events by about 10%.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: